<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">4376</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url">http://dx.doi.org/10.31782/IJCRR.2022.14411</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>&#13;
	A Specific LC-ESI-MS/MS Method Development and Validation for the Quantification of Saquinavir in Biological Matrices&#13;
&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Bandaru Anil</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ramesh</surname><given-names>Bomma</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>15</day><month>02</month><year>2022</year></pub-date><volume>)</volume><issue/><fpage>63</fpage><lpage>68</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>&#13;
	Introduction: Saquinavir is the first protease inhibitor. Proteases are enzymes that cleave protein molecules into smaller fragments. No analytical procedure was reported for the estimation of saquinavir by LC-MS/MS. Aims: The objective of the present research was to develop a specific liquid chromatography-electrospray ionization tandem mass spectrometric technique for the quantitation of saquinavir in biological matrices. Methodology: Chromatographic elution was attained thru a Thermo Hypersil ODS stationary column having the dimensions of 50 __ampersandsigntimes; 4.6 mm and particle size of 2.4 __ampersandsignmu;m. Isocratic elution was processed with methanol and 0.1%V/V formic acid in the ratio of 90:10 V/V as mobile phase with flow rate of 0.50 ml/min. Liquid-liquid extraction was performed for drug and internal standard isolation with an ethyl acetate solvent. Parent and productions were monitored at m/z 671.3 __ampersandsignrarr; 654.3 for saquinavir and 614.3 __ampersandsignrarr; 596.3 for indinavir internal standardon multiple reaction monitoring. Result: Linearity graph of drug was rectilinear in concentration over 260.4. to 10416ng/ml having r2(correlation coefficient) value more than 0.999. Percentage of RSD findings were __ampersandsignle;5.3% for inter and intraday accuracy and precision. This procedure has good recoveries and %recovery findings of lower quality control (LQC), median quality control (MQC) and higher quality control (HQC) samples were 94.6%, 92.4 and 104.2% respectively. Conclusion: Saquinavir has more stability for longer time when subjected for different stability environments and the technique was effectively relevant to routine analysis of saquinavir in biological matrix.&#13;
&#13;
</p></abstract><kwd-group><kwd>Protease inhibitor</kwd><kwd> Saquinavir</kwd><kwd> LC-ESI-MS/MS</kwd><kwd> FDA guidelines</kwd><kwd> Specificity</kwd><kwd> Linearity</kwd></kwd-group></article-meta></front></article>
